How can prescribers and other clinicians collaborate in order to help improve adherence to treatment to manage attention-deficit/hyperactivity disorder (ADHD)? And what keeps patients and their families from adhering to medication?
How can prescribers and other clinicians collaborate in order to help improve adherence to treatment to manage attention-deficit/hyperactivity disorder (ADHD)? And what keeps patients and their families from adhering to medication? Thomas E. Brown, PhD, presented about this topic at the 2018 Annual Meeting of The American Professional Society of ADHD and Related Disorders (APSARD) in Washington, DC, in January.
Studies show that among both children and adults, there is low adherence to medication treatment for ADHD. Many patients do not take the medications consistently, Brown said, or they don’t get prescriptions refilled. There are several reasons for this, he said in his presentation called "Collaboration Between Prescribers and Other Clinicians In Managing ADHD."
Patients or families may have insufficient or an unrealistic understanding of how stimulant and non-stimulant medications work, and how they may help.
For prescribers who prescribe ADHD medicine (psychiatrists, pediatricians, general practitioners), there are other challenges, Brown said, mostly involving time.
In addition, because stimulant medicines are Schedule II medicines, some providers may have liability concerns.
Non-prescribing clinicians, like psychologists or social workers, may have insufficient training about ADHD medicines and the variety of factors that impact one’s individual responses to the medications. They may have an insufficient understanding of prescriber concerns about liability, and they may have difficulty in communicating with prescribers.
However, non-prescribing clinicians who are what Brown called “adequately prepared” in this area can act as a go-between with patients and prescribers, by:
One common misunderstanding has to do with how many people understand ADHD to be a chemical problem in the brain. That oversimplifies it, Brown said, ADHD is far more complex than that.
He told his audience some still believe ADHD is "a chemical imbalance in the brain—too much or too little,” or “You take some medicine to fix the imbalance and then you’re OK.” It leads to a myth that “you can fix a chemical imbalance in the brain like there’s too much salt in the soup,” said Brown. “It’s much more complicated than that.”
Rather than single neurons talking to each other, he likened communication within the brain to be more of a symphony across regional communications networks, with some signals in the brain stronger than others. The signals differ in strength based on how important the brain thinks the signal is, he said.
Moreover, the way medicine works has nothing to do with age, weight or symptom severity. Medicine works according to the sensitivity of the body’s chemicals to that medicine, absorption and metabolizing speed, what other medicines are in the body (both legal and illegal), and patient expectations (ie, the placebo effect).
All of this has to be conveyed to the patient, he said, and medications, dose and timing need to be adjusted to individual needs, body chemistry and schedule.
Brown was previously on the clinical faculty at Yale Medical School and recently relocated to California, where he is adjunct clinical associate professor of psychiatry and behavioral sciences at the Keck School of Medicine of the University of Southern California.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More